FDA gives ocrelizumab breakthrough designation for PPMS: Roche

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUSTM) for treating people with primary progressive multiple sclerosis (PPMS), Swiss drugmaker Roche said on Wednesday.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro